Antibody Market

Antibody Market Outlook for 2024 to 2034

The global antibody market size is estimated to be worth around 266.83 billion in 2024. The total market value of the antibodies sector is anticipated to increase at a CAGR of 8.1% from 2024 to 2033. Furthermore, it is anticipated that the market for antibodies will reach USD 581.42 billion by 2034. The total market growth of the antibodies sector represented in absolute dollars is USD 315 billion.

Report Attribute	Details
Antibody Market Size (2024)	USD 266.83 billion
Market Anticipated Forecast Value (2034)	USD 581.42 billion
Market Projected Growth Rate (2024 to 2034)	8.1% CAGR

Antibody Market Trends & Analysis

• As the prevalence of autoimmune diseases is on the rise, the demand for antibody drugs has strengthened over the last couple of years. Moreover, the rising application of antibodies in chronic disease treatment is anticipated to create more opportunities for antibody market expansion in the near future.
• Novel biosimilar antibody manufacturers are slashing their prices to compete with branded antibody manufacturers, especially in the European market. With the expiration of patents of renowned products, a boost in demand for biosimilar antibodies can be expected in upcoming years.

Global Antibody Market Historical Analysis (2019 to 2023) Vs Forecast Outlook (2024 to 2034)

The global antibody market was valued at USD 131.47 billion in 2019. The market overview of antibody drugs progressed at an annual rate of 12.5% between 2019 and 2023. The overall market value was about USD 236.86 billion by 2023.

Attributes	Details
Antibody Market Value (2019)	USD 131.47 billion
Market Revenue (2023)	USD 236.86 billion
Market Historical Growth Rate (CAGR 2019 to 2023)	12.5% CAGR

Growth Opportunities Witnessed by the Global Antibody Market Participants

Research and Development Activities Impact Antibodies Sales Outlook

A surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies is driving growth opportunities for diagnostic specialty antibody suppliers.

In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health's rapid test contract development and manufacturing services.

Rising cases of multiple sclerosis and Parkinson's disease among the older population is a key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, advanced genetic engineering technology, and novel and effective treatments in middle-income countries.

In 2021, Berkeley Lights, a digital cell biology company, joined hands with Genovac, an antibody discovery company, to readily access the right antibodies in the shortest amount of time with the help of modern technology.

Increasing Production of Bio-similar Antibodies is Driving Demand

Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies, and they have very few side effects. In 2020, Johnson and Johnson reported USD 3.75 Billion achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade, generated USD 659 million in 2020.

USA Food and Drug Administration (FDA) approved a biosimilar of Remicade called Avsola in December 2019 and is now eligible for producing biologics products all over the world. Increasing demand for biosimilar antibodies in the treatment of rheumatoid arthritis, along with a high patient acceptance rate, is anticipated to boost the market growth for antibodies.

One of the leaders in prescription medicines, Pfizer, received EU approval for biosimilar antibody therapeutics Amsparity for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020. Elevated new drug approval rates and products in clinical trials in pharmaceutical companies are anticipated to further drive the market in the upcoming years.

Country-wise Insights

The table below mentions the countries that are expected to witness higher growth opportunities in this market.

Regional Market Comparison	CAGR (2024 to 2034)
United States	9.6%
Germany	9.4%
United Kingdom	10.1%
India	9.5%
China	6.5%

Advancement in Therapeutics is driving the Market in the United States

The United States therapeutic antibodies market is poised to advance at a rate of 10.1% per year till 2034.

• Modern healthcare infrastructural facilities and the presence of leading market players in the United States.
• Autoimmune diseases are the third most common reason for chronic ailments creating a higher demand for antibody drugs in the country.

The Medical Tourism Sector has boosted Antibody Consumption in the United Kingdom

Consumption of antibody products in the United Kingdom is projected to rise at a rate of 10.1% during the forecast years.

• Higher disease prevalence as well as the United Kingdom citizens’ capacity for spending on cutting-edge medicines.
• The rapidly improving medical tourism sector of the country is projected to drive the demand for antibodies in the coming days.

Rising Elderly Population Percentage is fueling Antibodies Sales Outlook in China

The antibodies industry in China is projected to thrive at a CAGR of 5.8% through the projected years.

• Growing awareness about the benefits of antibodies for various medical ailments like rheumatoid arthritis, cancer, and infections.
• The rising geriatric population and associated ailments are anticipated to drive market growth for antibodies in the upcoming years.

Germany Antibodies Therapeutics Market Size Expanding with Rising Cancer Cases

Sales of antibodies in Germany are anticipated to increase at a rate of 9.4% from 2024 to 2034.

• A surge in cancer patients is anticipated to drive the demand for antibodies for cancer treatment.
• Germany's antibody drugs market has strengthened significantly with the presence of top companies, whose products are in great demand worldwide.

Government Funding has Bolstered Antibodies Development and Production in India

Demand for antibodies in India is expected to rise at a rate of 9.5% per year between 2024 and 2034.

• Rising cases of cancer and cardiovascular diseases along with the development of the healthcare system in the country.
• Increasing government funding to make the treatment affordable, and increasing consumer spending on healthcare are anticipated to create more opportunities.

Category-wise Insights

Monoclonal Antibodies are More Effective than Polyclonal Antibodies

Based on product type, the monoclonal antibodies market segment is estimated to account for 95% of the market share in 2024.

Attributes	Details
Top Product Type or Segment	Monoclonal Antibodies
Total Market Share in 2024	95%

• This segment is bolstering in response to the increasing cases of rheumatoid arthritis, psoriasis, and asthma in the geriatric population across the globe.
• Hospitals are anticipated to remain the dominant end user of monoclonal antibodies on account of rising cases of various types of chronic ailments.

Recombinant Antibodies are Primarily Used for Cancer Treatment

Based on disease indication, the use of antibodies for treating cancer is expected to account for 57% of the total sales in 2024.

Attributes	Details
Top Disease Indication Type or Segment	Cancer
Total Market Share in 2024	57%

• The rising prevalence of non-Hodgkin lymphoma and other types of cancer has fuelled the demand for cancer antibodies for developing non-invasive and safe treatment options.
• With the focus on cancer research increasing, the antibodies sales outlook for the upcoming decade is anticipated to remain positive.

Competitive Landscape for Antibody Market

Leading market players are working towards developing new antibodies to remain competitive in the present market. They are also researching to create long-acting antibody drugs to reduce healthcare costs and attract chronic patients.

In order to gain a competitive edge in the antibody testing market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic mergers and acquisitions for portfolio expansion are in the cards as well.

Startups Should Concentrate on Increasing the Scope of Their Research to Promote Innovation

Future market players should concentrate on acquiring additional money through financing rounds to broaden their research and company scope. New businesses are looking into how to leverage cutting-edge technologies to streamline the creation of therapeutic antibodies, including nanobodies and monoclonal antibodies.

• Great Bay Bio (GBB), a start-up with headquarters in Hong Kong, declared in September 2022 that it had successfully raised USD 15 million in its Pre-series B investment round. The financing is to be put to use by the business to quicken the creation of bioprocessing platforms that are powered by artificial intelligence (AI) in order to enhance the CMC process for a variety of biological pharmaceuticals, such as monoclonal antibodies and fusion proteins.
• Capstan Therapeutics, a startup with the goal of creating treatments for conditions with unmet medical needs, declared its launch in September 2022 and provided USD 165 million for in-vivo cell engineering. The business is creating in-vivo CAR treatments, which allow for cell engineering while the patient is still receiving treatment.
• Versant Ventures, a well-known investor in biotechnology startups, announced a new relationship with AbCellera, a business specializing in antibody development, in July 2022. Through this collaboration, Versant has significantly sped up the research and development process by supplying start-ups with antibodies from AbCellera that are tailored to their target disease.

Recent Developments in the Global Antibody Market

• Research: Investigational Oral Treatment

On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment iptacopan, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that during 12 weeks of iptacopan monotherapy treatment, no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.

• Acquisition: Johnson & Johnson and Momenta Pharmaceuticals Inc.

In August 2020, Johnson & Johnson entered into a final agreement to acquire Momenta Pharmaceuticals Inc. for around USD 6.5 Billion. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.

The acquisition may allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth opportunities through expansion into autoantibody-driven disease.

• Partnership: Sanofi and IGM Biosciences

Leading pharmaceutical company Sanofi announced in March 2022 that it will collaborate with IGM Biosciences to research, produce, and market six novel immunoglobulin M antibody agonists. Sanofi has agreed to approximately USD 6 billion in possible milestone payments through this agreement.

Key Players Profiled in the Antibody Market Report

• Novartis AG
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• Amgen Inc.

Key Coverage in the Antibody Market Report

• Adjacent study on research antibodies & reagents market.
• Comparative analysis of antibody vs. antigen market.
• Antibody market potential in African nations.

Antibody Market Report Scope

Attribute	Details
Estimated Market Size (2024)	USD 266.83 billion
Projected Market Size (2034)	USD 581.42 billion
Anticipated Growth Rate (2024 to 2034)	8.1%
Forecast Period	2024 to 2034
Historical Data Available for	2019 to 2023
Market Analysis	USD million or billion for Value and Units for Volume
Key Regions Covered	North America; Latin America; Europe; Middle East & Africa (MEA); East Asia; South Asia and Oceania
Key Countries Covered	United States, Canada, Brazil, Mexico, Germany, Spain, Italy, France, United Kingdom, Russia, China, India, Australia & New Zealand, GCC Countries, and South Africa
Key Segments Covered	By Product Type, By Disease Indication, By End Use Verticals, and By Region
Key Companies Profiled	Novartis AG; F. Hoffmann-La Roche AG; Johnson & Johnson; Takeda Pharmaceutical Company Limited; Amgen Inc.
Report Coverage	Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing	Available upon Request

Key Segments Covered by Antibodies Industry Survey Report

By Disease Indication:

• Cardiovascular Diseases
• CNS Disorders
• Cancer
• Autoimmune Disorders
• Other Disease Indications

By Product Type:

• Monoclonal Antibodies
• Polyclonal Antibodies
• Antibody-drug Complexes

By End User:

• Hospitals
• Long-term Care Facilities
• Research Institutes
• Other End Users

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia and Pacific
• Middle East and Africa (MEA)

Frequently Asked Questions

How Big is the Global Antibody Market Currently?

The global antibody market is estimated to be around USD 266.83 billion in 2024.

What is the Growth Outlook of the Antibody Market?

The global antibody market is to grow at 8.1% during the forecast period.

What is the projected Value of Antibody Market by 2034?

The global antibody market is predicted to be valued at USD 581.42 billion by 2034.

What was the Historical Size of the Antibody Market?

The global antibody market was valued at USD 131.47 billion in 2019.

Which Regional Antibody Market has the Highest Growth Potential?

The United Kingdom to witness 10.1% CAGR in sales of antibodies through 2034.